Company Overview and News

 
RBA / Ritchie Bros. Auctioneers Inc. FORM 8-K (Current Report)

2018-09-13 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
RBA

 
Ritchie Bros. (RBA) Soars: Stock Adds 8.1% in Session

2018-08-13 zacks
Ritchie Bros. Auctioneers Incorporated (RBA - Free Report) was a big mover last session, as the company saw its shares rise more than 8% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $32.02 to $34.80 in the past one-month time frame.
RBA REI LQDT

 
Ritchie Bros. Auctioneers' (RBA) CEO Ravi Saligram on Q2 2018 Results - Earnings Call Transcript

2018-08-12 seekingalpha
Ritchie Bros. Auctioneers Inc. (NYSE:RBA) Q2 2018 Earnings Conference Call August 10, 2018 11:00 AM ET
RBA

 
Canadian Dividend All-Stars Expected To Announce Dividend Increases - Week Of Aug 13

2018-08-11 seekingalpha
6 All-Stars raised dividends last week, while one lost its status as a dividend growth company.
SAPIF RBA HDIUF KEYUF FSZ SAP CIFAF LTKBF EMA FRRPF EMRAF CAE KEY CIX RBA

 
Canadian Dividend All-Stars Expected To Announce Dividend Increases - Week Of Aug 8

2018-08-05 seekingalpha
The month of July only saw one Canadian Dividend All-Star, Alimentation Couche-Tard, announce a dividend increase. Fret not, the summer lull is about to come to an end. It all begins this week where two All-Stars are expected to raised dividends. There are several others overdue for a raise who are also scheduled to report earnings.
RBA TRI SAPIF ANCUF HDIUF ANCTF KEYUF FSZ CIFAF ATD.A ATD.B KEY CIX RBA TRI

 
ANZ Banking Group: I'm Taking The Profit

2018-07-04 seekingalpha
Interest rates were left unchanged again this week, continuing a streak started over twenty meetings ago.
RBA

1
Ritchie Bros. Auctioneers Incorporated (RBA) Sees Hammer Chart Pattern: Time to Buy?

2018-05-14 zacks
Ritchie Bros. Auctioneers Incorporated (RBA - Free Report) has been struggling lately, but the selling pressure may be coming to an end soon. That is because RBA recently saw a Hammer Chart Pattern which can signal that the stock is nearing a bottom.
RBA ISRG

1
Ritchie Bros. Auctioneers Inc. 2018 Q1 - Results - Earnings Call Slides

2018-05-11 seekingalpha
The following slide deck was published by Ritchie Bros. Auctioneers Inc. in conjunction with their 2018 Q1 earnings call.
RBA

1
RBA / Ritchie Bros. Auctioneers Inc. FORM 10-Q (Quarterly Report)

2018-05-10 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
RBA

7
5 Great Business Services Stocks to Buy Ahead of Q1 Earnings

2018-05-03 zacks
As markets growth increasingly volatile, fueled primarily by inflationary fears, it is easy to forget that the economy remains on a firm footing. Fresh evidence of this fact was provided by the ADP report for April which revealed that job additions had come in above 200,000 for the six straight month. Incidentally, professional and business services contributed nearly half of all the job additions experienced during April.
LNT RBA TRI BAH BKI

404
7 Best Platform Stocks to Buy Now | InvestorPlace

2018-04-05 investorplace - 1
What are platform stocks? Which are the best platform stocks to buy and how can they make you rich?
RDFN BABA RBA ZG AMZN Z AAPL AXP MSFT

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to RBA / Ritchie Bros. Auctioneers Inc. on message board site Silicon Investor.

Ritchie Bros. (RBA) Ritchie Bros. (RBA) Ritchie Bros. (RBA) UI.V - Urbanimmersive Technologies UI.V - Urbanimmersive Technologies UI.V - Urbanimmersive Technologies
HERBALIFE HERBALIFE HERBALIFE Ariba Technologies (Nasdaq-ARBA) Ariba Technologies (Nasdaq-ARBA) Ariba Technologies (Nasdaq-ARBA)
DROOY Durban Deep- Best S. African Mine DROOY Durban Deep- Best S. African Mine DROOY Durban Deep- Best S. African Mine New Urbanism New Urbanism New Urbanism
Hansen Natural Corp - Vitamin/Herbal Beverage Co Hansen Natural Corp - Vitamin/Herbal Beverage Co Hansen Natural Corp - Vitamin/Herbal Beverage Co Redback Networks, Inc. (RBAK) Redback Networks, Inc. (RBAK) Redback Networks, Inc. (RBAK)
Garbage Internet Stocks: Short the hype! Garbage Internet Stocks: Short the hype! Garbage Internet Stocks: Short the hype! Marimba, Inc. (MRBA) Marimba, Inc. (MRBA) Marimba, Inc. (MRBA)
CUSIP: 767744105